Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
ABSTRACT Neuropathic pain frequently occurs in cancer patients, but no drug therapy has been established for this type of disorder. The purpose of this study was to investigate the effect of duloxetine in cancer patients suffering from neuropathic pain.
The subjects of the study were 15 cancer patients with neuropathic pain who visited the Kinki University Faculty of Medicine Hospital and met the International Association for the Study of Pain diagnostic criteria for neuropathic pain. Duloxetine was administered to patients in whom pregabalin could not be administered. The influence of duloxetine was investigated retrospectively with the use of a numerical rating scale.
Pain was reduced in 7 out of the 15 patients. Sleepiness and the light-headed feeling were improved in four patients, in whom, however, the pain was not reduced. Thus, duloxetine was judged to be effective in 11 patients. The maintenance dose of duloxetine was 20-40 mg/day.
Duloxetine administration may be effective for neuropathic pain in cancer patients who cannot tolerate pregabalin administration.
- SourceAvailable from: Shivani Shinde[Show abstract] [Hide abstract]
ABSTRACT: Cancer pain is complex, and despite the introduction of the WHO cancer pain ladder, few studies have looked at the prevalence of adjuvant medication use in an inpatient palliative medicine unit. In this study, we evaluate the use of adjuvant pain medications in patients admitted to an inpatient palliative care unit and whether their use affects pain scores or opiate dosing.Supportive Care Cancer 08/2014; 23(3). DOI:10.1007/s00520-014-2415-9 · 2.50 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Abstract We evaluated Bortezomib Induced Peripheral Neuropathy (BIPN) characteristics in an attempt to better clarify the type, grade, duration and reversibility of neuropathy as well as to investigate possible peripheral neuropathy (PN) risk factors and to detect the best way to manage it. We calculated the grading of neuropathy by Total Neuropathy Score reduced version (TNSr), in a series of fifty-one relapsed/refractory multiple myeloma patients treated with Bortezomib. Seventy percent developed clinical PN.BIPN although manageable is frequently underestimated in patients treated by bortezomib intravenously. Continuous follow-up and management of PN are needed to avoid quality of life impairment.Leukemia & lymphoma 02/2014; 55(10). DOI:10.3109/10428194.2013.873535 · 2.61 Impact Factor